

## ISIGNTHIS

Veröffentlichung der ASX-Meldung von iSignthis vom 16. Juni 2019

16. Juni 2019

### Der Service Paydentity auf Wachstumskurs

iSignthis veröffentlichte heute eine ASX-Meldung zur Entwicklung seiner Paydentity-Services. Die Original-Meldung kann [HIER](#) abgegrufen werden.

#### Highlights

- **Das patentierte AML<sup>1</sup> KYCC<sup>2</sup> System generiert auch weiterhin Anwendungen**
- **Mehr als 150 Anwendungen sind inzwischen genehmigt und meldepflichtig**
- **Paydentity wird auch im Rahmen des KYB<sup>3</sup>-Prozesses genutzt, um Direktoren und den wirtschaftlichen Eigentümer zu identifizieren**

iSignthis Service Paydentity® wächst weiter. So vermeldete das Unternehmen in seiner heutigen Unternehmensmeldung, dass inzwischen mehr als 150 meldpflichtige Kunden den Service nutzen. Der Fokus im Mai lag dabei auf komplexeren und größeren Unternehmen.

Bei der Paydentity™ Services von iSignthis handelt es sich um eine Backoffice-Lösung für regulierte Unternehmen. Der Service hilft den Unternehmen, Regulierungen und Vorgaben im Bereich der Geldwäschebekämpfung, Kundenidentifikation, KYB (Know your Business), KYC (Know your Customer) sowie KYCC (Know Your Customers's Customer) einzuhalten. So kann ein für ein reguliertes Unternehmen verpflichtender KYC (Know Your Customer)-Prozess zwischen 3-21 Tage in Anspruch nehmen. Paydentity™ reduziert laut Angaben von iSignthis diesen Zeitraum auf 3-5 Minuten.

Der Paydentity Service bleibt auch weiterhin der

<sup>1</sup> AML = Anti Money Laundering = Geldwäschebekämpfung

<sup>2</sup> KYCC = Know Your Customer's Customer

<sup>3</sup> KYB = Know Your Business

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of this firm or any member or employee thereof.

This paper is a marketing communication only and does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in any of the companies listed, nor is it an inducement to make an offer or invitation with respect to any of the securities within. This information is intended solely for professional investors in the capital markets. The paper is not meant for private investors or other groups and is not to be forwarded to them. Please take note of this disclaimer.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

### 6-Monats-Chart iSignthis



Quelle: Comdirect

Börsen:	ASX & FRA
Code:	ASX: ISX / FRA:TA8
Marktk.	704 Mio. AU\$ / 410 Mio. €
GICS ind. group:	Software & Services
Performance:	+73% (3-Monate)
Ø-Handelsvolumen:	977T \$ (Ø- 100 Tage)

### Unternehmenskennzahlen

<b>Umsatz:</b>	6,1 Mio. AU\$ (2018); 1,2 Mio. AU\$ (2017)
<b>Verlust:</b>	-8,0 Mio. AU\$ (2018); -5,0 Mio. AU\$ (2017)
<b>Loss per share:</b>	1,0 Cent (2018); 0,78 Cent (2017)
<b>Cash<sup>5</sup>:</b>	8,4 Mio. AU\$ (31. Dez 18)

## ISIGNTHIS

Veröffentlichung der ASX-Meldung von iSignthis vom 16. Juni 2019

16 Juni 2019

wichtigste kommerzielle Treiber für neue Business-Applications. Die patentierte Payidentity® Technologie von iSignthis hilft Unternehmen, ihre Verpflichtungen zur **Geldwäschebekämpfung** nachzukommen, und im besonderen ihrer Verpflichtung zur **Kundenidentifikation** sowohl für den Endnutzer wie auch für den Businesspartner.

Die Kundenidentifikation beinhaltet sowohl die Identifizierung wie auch die Prüfung der Endnutzer oder Kunden sowie weitere Business-Teilnehmer in der Wert- bzw. Lieferkette. So können im Rahmen dieses Identifikationsprozesses bspw. die ultimativen wirtschaftlichen Eigentümer und Direktoren die möglicherweise hinter einem Business-Partner stehen, identifiziert werden.

Der **KYB (Know Your Business)-Prozess** ist für Unternehmen verpflichtend, die in der Wertschöpfungskette zwischen dem Kunden und dem Händler stehen. Beispiele sind Unternehmen, die Services im Bereich der Zahlungsabwicklung, Kredite, „Buy now, Pay later“, Marktplätze und eMoney-Services anbieten. Dabei ist dieser KYB (Know Your Business)-Prozess eine zwingende Anforderung sowohl unter den EU wie auch den Australischen regulatorischen Anforderungen und ist dabei meist die langsamste und schwierigste Komponente im Kunden-Akquisitions-Prozess.

iSignthis nutzt Payidentity® ebenfalls im Rahmen des **KYCC (Know Your Customer's Customer)-Prozesses**. Im Rahmen dieses Prozesses werden die Kunden der Händler, mit welchen iSignthis zusammenarbeitet, identifiziert. Dabei wird eine **Customer Due Diligence (CDD)** vorgenommen, in welcher die Kunden der Händler identifiziert werden. Hierdurch können die Händler ihre regulatorischen Verpflichtungen einer Customer Due Diligence nachkommen.

In Australien erfüllt Payidentity® die CDD (Customer Due Diligence)-Anforderungen der Geldwäschebekämpfung sowie der Vorschriften zur Terrorismusbekämpfung. Der iSignthis KYCC (Know Your Customer's Customer)-Prozess, welcher durch den Service Payidentity® angeboten wird, ermöglicht es den Kunden von iSignthis, den regulatorischen Anforderungen des AUSTRAC<sup>1</sup> bzw. der europäischen regulatorischen Anforderungen genüge zu leisten.

---

<sup>1</sup>AUSTRAC = Australian Transaction Reports and Analysis Centre

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of this firm or any member or employee thereof.

This paper is a marketing communication only and does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in any of the companies listed, nor is it an inducement to make an offer or invitation with respect to any of the securities within. This information is intended solely for professional investors in the capital markets. The paper is not meant for private investors or other groups and is not to be forwarded to them. Please take note of this disclaimer.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

**DR REUTER INVESTOR RELATIONS**

SPEZIALIST IN INVESTOR RELATIONS WORK ON THE EUROPEAN CAPITAL MARKETS  
 FRIEDRICH EVERT ANLAGE 35-37  
 TOWER 185  
 60327 FRANKFURT  
 DR. EVA REUTER, TEL. +49 251 7 32 862  
 E.REUTER@DR-REUTER.EU

**Disclaimer**

The information and opinions given in this note have been drawn up by Dr. Reuter Investor Relations. This note has been exclusively published for informative purposes and represents neither a request, quotation nor a recommendation for buying or selling investment instruments or for effecting other transactions. Moreover, neither this publication nor its information forms the basis for a contract or a commitment of any kind. Any investment in shares, loans and options is faced with risks.

The information and data come from sources which Dr Reuter Investor Relations considers to be reliable. However, Dr Reuter Investor Relations do not assume any responsibility for the correctness and completeness of the information and data. Neither the writer nor Dr. Reuter Investor Relations are liable for losses or damage of any kind in connection with the content of this information brochure. By accepting this document you agree to the provisions previously noted as being mandatory for the recipient. Share prices can vary and corporate value can rise/fall. Any reference to the previous trend in value is not necessarily an indicator of developments to come. Rates of exchange can adversely affect the value trend, price and earnings of any company mentioned here. Reference is also made here to possible political, economic, credit, foreign exchange and market risks. Investment in any of the companies mentioned should only be done after studying the most recent brochure and other company/market information available and /or obtaining appropriate professional advice. Corporate brochures can be obtained from the companies in question. The reader should evaluate any investment in any of the companies mentioned there in the light of their own professional advice, circumstances and investment goals. The recommendation of Dr Reuter Investor Relations - in the event of any investments - is to consult a qualified professional consultant as to the specific financial risks and the statutory, official, credit, fiscal and settlement-induced consequences. It is quite possible that the issuers of the securities mentioned here have acted at variance to the facts of the case specified herein without Dr. Reuter Investor Relations being

aware of this development.

In drawing up this paper, the following conflicts of interest cannot be categorically ruled out:

1. The companies specified may be Dr. Reuter Investor Relations customers and this publication is undertaken as part of the investor relations service package.
2. This publication was presented to the companies specified before publication and may have been changed at the company's request.
3. Dr Reuter Investor Relations and/or an affiliated company or the writer may have long or short positions in the companies specified.

This paper includes the following possible conflicts of interest: iSignthis is a customer of Dr. Reuter Investor Relations.

Some of the following detailed statements are based on translations of corporate news and company documentation. No liability is assumed for the translations. Please refer to the original English notifications and original documents.

**Disclaimer United States:**

1. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
2. This news release does not constitute an offer to sell or other solicitation of an offer to buy any ordinary shares within the United States. The ordinary shares have not been offered and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws. Accordingly, the ordinary shares may not be offered or sold in the United States or to U:S Persons (as such terms are defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is granted.
3. Information and investment comments are independently and thoroughly researched and believed correct. No guaranty of absolute accuracy can be given however. Investment decisions are fully made for own risk.